Pro Medicus share price fails to fly on 44% profit leap

Here's how Pro Medicus dialled up the profits in FY22.

| More on:
Three medical staffers sit at a table and chat happily wearing hospital scrubs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price is inching 0.5% higher to $54.04 today
  • Profits increased a sizeable 44% year over year to $44.4 million
  • CEO Dr Sam Hupert hinted at a strong pipeline and potential for future acquisitions

The Pro Medicus Limited (ASX: PME) share price is splashing about to little avail on Thursday as investors react to the company's full-year results for FY22.

Around midday, shares in the medical imaging software provider are sporting a slight 0.5% increase. The Pro Medicus share price is now $54.04. For context, the S&P/ASX 200 Index (ASX: XJO) is down 0.22%.

Pro Medicus share price staggers on solid result

Key highlights in the report are as follows:

  • Revenue up 37.7% year over year to $93.5 million
  • Earnings before interest and tax (EBIT) margin of 67.5%, up from 63%
  • Net profit after tax (NPAT) up 44.1% to $44.4 million
  • Fully franked final dividend of 12 cents per share declared
  • Total dividends for FY22 up 47% to 22 cents per share fully franked
  • Cash and other financial assets increased 47% to $90.6 million.

ASX investors are largely unamused by the news released by Pro Medicus today. Despite the results representing another record for revenue and profits, shares are staggering above and below yesterday's closing price.

What else happened in FY22?

It was a busy financial year for the team at Pro Medicus in FY22. The 12-month period consisted of a mix between new deal signings and significant contract renewals.

Noteworthy new deals involved prominent healthcare providers including Novant Health, Inova Health, and Allina Health. All three of these contracts with the United States-based operators were for seven or eight years. The combined value over the life of the initial agreements amounts to $100 million.

Meanwhile, key renewals during the reporting period included those with Sutter Health and Wellspan. Pleasingly, the agreed term was for an additional five years at a combined value of $47 million.

Moreover, Pro Medicus landed its fourth extension for the provision of its Visage 7.0 platform to the German Government.

What did management say?

Commenting on the results, Pro Medicus CEO Dr Sam Hupert said:

FY22 year was another year where all our key financial metrics headed in the right direction and we continued to make significant progress with key implementations. All three jurisdictions did very well. North America – our biggest market – was the key contributor, with a 65% jump in transaction revenue coupled with three new material contracts and two contract renewals.

Additionally, Hupert highlighted that revenue from recent contract wins — such as Novant, Inova, and Allina Health — will begin in FY23.

What's next?

Becoming a somewhat common theme this earnings season, Pro Medicus did not provide any forward guidance. Although, Dr Hupert did note that the company's contract pipeline remains 'strong'.

The CEO also noted that interest from the for-profit sector has picked up again after dropping off from COVID-19 impacts.

Finally, management pointed out the possibility of future merger and acquisition opportunities amid compressed company valuations. Namely, potential in artificial intelligence (AI) startups that are pre-revenue and not profitable.

With more than $90 million of financial fodder on its balance sheet, Pro Medicus would be primed for any such activity.

Pro Medicus share price snapshot

As with most premium-valued companies, 2022 has been relatively unkind to the Pro Medicus share price. The shares have fallen around 14% since the beginning of the year. Whereas, the S&P/ASX 200 Health Care Index (ASX: XHJ) has only tip-toed 4.4% lower.

Lastly, despite the sizeable boost in earnings, Pro Medicus still trades on a price-to-earnings (P/E) ratio of approximately 127 times. For comparison, the average for the global healthcare services industry is 40.6 times.

Motley Fool contributor Mitchell Lawler has positions in Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Earnings Results

Westpac shares on watch amid $6.99b profit and new buyback

Has the big four bank delivered the goods for investors this year? Let's find out.

Read more »

Woman inspecting packages.
Earnings Results

This top 50 ASX stock is diving 5% despite a strong outlook

Investors were looking for more.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Earnings Results

Macquarie share price sinks despite $1.6b half year profit and new buyback

How did this investment bank perform during the first half? Let's find out.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Earnings Results

Why the BrainChip share price is in the spotlight this week

Today's reaction is in stark contrast to the day of the release.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A businesswoman ponders why her boat is sinking in the ocean.
Resources Shares

Lake Resources share price sinks on quarterly cash flow news

Let's take a look at the highlights of the company's Q3 update.

Read more »

Lithium ion batteries
Earnings Results

Needs a recharge: Novonix share price sees red after Q3 earnings

Investors were likely expecting a tad more.

Read more »

chip and tech stocks represented by two computer chips side by side
AI Stocks

Up 237% in 2024, why is the Appen share price racing higher again today?

Investors are bidding up Appen shares again today. But why?

Read more »